Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 3, 2012, Pages 617-627

  Glaser, Keith B ^a   Li, Junling ^a   Marcotte, Patrick A ^a   Magoc, Terrance J ^a   Guo, Jun ^a   Reuter, David R ^a   Tapang, Paul ^a   Wei, Ru Qi ^a   Pease, Lori J ^a   Bui, Mai H ^a   Chen, Zehan ^a   Frey, Robin R ^a   Johnson, Eric F ^a   Osterling, Donald J ^a   Olson, Amanda M ^a   Bouska, Jennifer J ^a   Luo, Yanping ^a   Curtin, Michael L ^a   Donawho, Cherrie K ^a   Michaelides, Michael R ^a   Tse, Chris ^a   Davidsen, Steven K ^a   Albert, Daniel H ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO N [3 [[3 (4 CHLORO 2 FLUOROPHENYL)UREIDO]METHYL]PHENYL]THIENO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE; A 993352; AURORA B KINASE; AURORA KINASE INHIBITOR; BARASERTIB; HISTONE H3; ILORASERTIB; IMATINIB; LINIFANIB; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; BLOOD VESSEL PERMEABILITY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FIBROSARCOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUTATION; NONHUMAN; PANCREAS CARCINOMA; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN TARGETING; SOLID TUMOR; UTERINE EDEMA;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTONES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUKEMIA, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; MOLECULAR STRUCTURE; NIH 3T3 CELLS; PHENYLUREA COMPOUNDS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SRC-FAMILY KINASES; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869210239     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.197087     Document Type: Article

References (54)

1. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, et al. (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5:995-1006. (Pubitemid 43724600)
2. Alitalo K, Tammela T, and Petrova TV (2005) Lymphangiogenesis in development and human disease. Nature 438:946-953. (Pubitemid 43093960)
3. Andrews PD (2005) Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24:5005-5015.
4. Baka S, Clamp AR, and Jayson GC (2006) A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10:867-876. (Pubitemid 44816749)
5. Bass MB, Sherman SI, Schlumberger MJ, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, Notari KH, Peach M, Hei YJ, et al. (2010) Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 95:5018-5027.
6. Bhargava P and Robinson MO (2011) Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 13:103-111.
7. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et al. (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052-3065. (Pubitemid 28254378)
8. Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, et al. (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14:352-359. (Pubitemid 351226100)
9. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, et al. (2007) PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6:3158-3168.
10. Carpinelli P and Moll J (2008) Aurora kinases and their inhibitors: more than one target and one drug, in Targeted Therapies in Cancer (Colotta F and Mantovani A eds) pp 54-73, Springer, NY.
11. Cheng JD and Weiner LM (2003) Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation proteinpositive cancer. Clin Cancer Res, 9: 1639-1647, 2003. Clin Cancer Res 9:1590-1595.
12. Clark JW, Eder JP, Ryan D, Lathia C, and Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480. (Pubitemid 41060823)
13. Curtin ML, Frey RR, Heyman HR, Soni NB, Marcotte PA, Pease LJ, Glaser KB, Magoc TJ, Tapang P, Albert DH, et al. (2012) Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. Bioorg Med Chem Lett 22:3208-3212.
14. Dai Y, Hartandi K, Ji Z, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, et al. (2007) Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 50:1584-1597. (Pubitemid 46564379)
15. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, et al. (2004) VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23:2800-2810. (Pubitemid 39013552)
16. Farag SS (2011) The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol 155:561-579.
17. Ferrara N, Gerber HP, and LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676. (Pubitemid 36749215)
18. Fong GH, Rossant J, Gertsenstein M, and Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70.
19. Fu J, Bian M, Jiang Q, and Zhang C (2007) Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5:1-10.
20. Giet R, Petretti C, and Prigent C (2005) Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol 15:241-250. (Pubitemid 40603893)
21. Girdler F, Sessa F, Patercoli S, Villa F, Musacchio A, and Taylor S (2008) Molecular basis of drug resistance in aurora kinases. Chem Biol 15:552-562. (Pubitemid 351815053)
22. Guo J, Anderson MG, Tapang P, Palma JP, Rodriguez LE, Niquette A, Li J, Bouska JJ, Wang G, Semizarov D, et al. (2009) Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152. Pharmacogenomics J 9:90-102.
23. Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, Davidsen SK, and Glaser KB (2006) Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 5:1007-1013. (Pubitemid 43724601)
24. Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, Newlander K, Adams JL, Dhanak D, Yang J, et al. (2009) GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 8:1808-1817.
25. Hienonen T, Salovaara R, Mecklin JP, Järvinen H, Karhu A, and Aaltonen LA (2006) Preferential amplification of AURKA 91A (Ile31) in familial colorectal cancers. Int J Cancer 118:505-508. (Pubitemid 41779093)
26. Johnson FM and Gallick GE (2007) SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7:651-659. (Pubitemid 350237770)
27. Kanda A, Kawai H, Suto S, Kitajima S, Sato S, Takata T, and Tatsuka M (2005) Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene 24:7266-7272. (Pubitemid 41622230)
28. Kelly KR, Ecsedy J, Mahalingam D, Nawrocki ST, Padmanabhan S, Giles FJ, and Carew JS (2011) Targeting aurora kinases in cancer treatment. Curr Drug Targets 12:2067-2078.
29. Kimura M, Matsuda Y, Yoshioka T, and Okano Y (1999) Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 274:7334-7340.
30. Koh TS, Thng CH, Hartono S, Tai BC, Rumpel H, Ong AB, Sukri N, Soo RA, Wong CI, Low AS, et al. (2011) A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy. NMR Biomed 24:1169-1180.
31. Kunz-Schughart LA and Knuechel R (2002) Tumor-associated fibroblasts (part I): active stromal participants in tumor development and progression? Histol Histopathol 17:599-621. (Pubitemid 34411214)
32. Kurai M, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, Suzuki A, and Konishi I (2005) Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 36:1281-1288. (Pubitemid 41682283)
33. Lewis CE and Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605-612. (Pubitemid 43165918)
34. Li S (2008) Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 49:19-26.
35. Luo Y, Jiang F, Cole TB, Hradil VP, Reuter D, Chakravartty A, Albert DH, Davidsen SK, Cox BF, McKeegan EM, et al. (2012) A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model. Cancer Chemother Pharmacol 69:911-921.
36. Luo Y, Smith RA, Guan R, Liu X, Klinghofer V, Shen J, Hutchins C, Richardson P, Holzman T, Rosenberg SH, et al. (2004) Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry 43:1254-1263. (Pubitemid 38176523)
37. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, et al. (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201. (Pubitemid 33063774)
38. McClellan WJ, Dai Y, Abad-Zapatero C, Albert DH, Bouska JJ, Glaser KB, Magoc TJ, Marcotte PA, Osterling DJ, Stewart KD, et al. (2011) Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases. Bioorg Med Chem Lett 21:5620-5624.
39. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al. (2006) Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and plateletderived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24. (Pubitemid 46630489)
40. Neufeld G, Cohen T, Gengrinovitch S, and Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22. (Pubitemid 29038270)
41. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, et al. (2005) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11:261-262. (Pubitemid 40460552)
42. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71-78.
43. Rafii S, Lyden D, Benezra R, Hattori K, and Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826-835. (Pubitemid 37328901)
44. Ramalingam SS and Belani CP (2010) Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. Curr Opin Oncol 22:79-85.
45. Roodink I and Leenders WP (2010) Targeted therapies of cancer: angiogenesis inhibition seems not enough. Cancer Lett 299:1-10.
46. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, and Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474-5483.
47. Schöffski P, Jones SF, Dumez H, Infante JR, Van Mieghem E, Fowst C, Gerletti P, Xu H, Jakubczak JL, English PA, et al. (2011) Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 47:2256-2264.
48. Slevin M, Kumar P, Wang Q, Kumar S, Gaffney J, Grau-Olivares M, and Krupinski J (2008) New VEGF antagonists as possible therapeutic agents in vascular disease. Expert Opin Investig Drugs 17:1301-1314.
49. Smith SL, Bowers NL, Betticher DC, Gautschi O, Ratschiller D, Hoban PR, Booton R, Santibáñez-Koref MF, and Heighway J (2005) Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 93:719-729. (Pubitemid 41486464)
50. Soltau J and Drevs J (2009) Mode of action and clinical impact of VEGF signaling inhibitors. Expert Rev Anticancer Ther 9:649-662.
51. Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, Spalletti-Cernia D, Laccetti P, Linardopoulos S, Chieffi P, et al. (2005) Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90:928-935. (Pubitemid 40279218)
52. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, and Kerbel RS (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61:5090-5101. (Pubitemid 32681540)
53. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, et al. (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13:3682-3688. (Pubitemid 46955132)
54. Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, et al. (2009) Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 27:4718-4726.